Related Experiment Video

Updated: Jun 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives]

F Pinto1, A Calarco, A Totaro

  • 1Urologia, Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma. francesco.pinto@libero.it

Urologia
|October 5, 2010
PubMed

Insights

Androgen-deprivation therapy is crucial for advanced prostate cancer but has side effects. Novel therapies and careful monitoring are essential for managing treatment outcomes and long-term health.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Androgens play a key role in prostate cancer development and progression.
  • Androgen-deprivation therapy (ADT) is a cornerstone treatment for advanced and metastatic prostate cancer.
  • ADT is also used with radiotherapy and surgery for locally advanced tumors.

Purpose of the Study:

  • To review the role of androgens in prostate cancer.
  • To discuss current ADT strategies, including intermittent suppression.
  • To highlight emerging therapies and long-term side effects of ADT.

Main Methods:

  • Literature review of androgen's role in prostate cancer.
  • Analysis of current ADT efficacy and limitations.
  • Evaluation of novel therapeutic approaches and side effect management.

Main Results:

  • ADT is effective but associated with side effects like testosterone surge, metabolic syndrome, and hormone resistance.
  • Newer agents like LH-RH antagonists, depot analogues, abiraterone acetate, and MDV3100 aim to mitigate flare-ups and treat castration-resistant prostate cancer.
  • Long-term ADT effects include osteoporosis, sarcopenic obesity, and cardiovascular issues requiring monitoring.

Conclusions:

  • ADT remains vital for prostate cancer treatment, necessitating management of its side effects.
  • Innovative therapies offer improved outcomes and reduced toxicity.
  • Comprehensive monitoring and management of long-term ADT complications are crucial for patient well-being.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...